Anirvan P, Khan Z, Bhuyan P, Dixit S, Dash R, Mishra P
J Clin Exp Hepatol. 2025; 15(3):102503.
PMID: 39996103
PMC: 11847462.
DOI: 10.1016/j.jceh.2025.102503.
Fishman J, Qian C, Kim Y, Rochon H, Szabo S, Sun R
J Manag Care Spec Pharm. 2024; 30(9):929-941.
PMID: 38845444
PMC: 11365567.
DOI: 10.18553/jmcp.2024.24069.
Park H, Yoon E, Kim M, Kim H, Kim M, Kim Y
Sci Rep. 2024; 14(1):7189.
PMID: 38531925
PMC: 10965918.
DOI: 10.1038/s41598-024-56085-3.
Behari J, Bradley A, Townsend K, Becich M, Cappella N, Chuang C
Dig Dis Sci. 2023; 69(2):370-383.
PMID: 38060170
DOI: 10.1007/s10620-023-08186-8.
Duseja A, Singh S, De A, Madan K, Rao P, Shukla A
J Clin Exp Hepatol. 2023; 13(2):273-302.
PMID: 36950481
PMC: 10025685.
DOI: 10.1016/j.jceh.2022.11.014.
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed.
Kasper P, Demir M, Steffen H
Clin Mol Hepatol. 2023; 29(2):390-393.
PMID: 36935647
PMC: 10121306.
DOI: 10.3350/cmh.2023.0059.
Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population.
Park H, Yoon E, Kim M, Lee J, Cho S, Won Jun D
Front Med (Lausanne). 2022; 9:1024836.
PMID: 36405611
PMC: 9668872.
DOI: 10.3389/fmed.2022.1024836.
Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.
Roeb E
Visc Med. 2022; 38(2):126-132.
PMID: 35614896
PMC: 9082206.
DOI: 10.1159/000519611.
Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
Dunn W, Song X, Koestler D, Grdinovac K, Al-Hihi E, Chen J
J Gastroenterol Hepatol. 2022; 37(9):1815-1821.
PMID: 35613944
PMC: 9543724.
DOI: 10.1111/jgh.15900.
Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups.
Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A
BMC Gastroenterol. 2022; 22(1):241.
PMID: 35562658
PMC: 9101936.
DOI: 10.1186/s12876-022-02290-1.
Nonalcoholic Fatty Liver Disease: Indian Perspective.
De A, Duseja A
Clin Liver Dis (Hoboken). 2021; 18(3):158-163.
PMID: 34691404
PMC: 8518336.
DOI: 10.1002/cld.1141.
Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?.
Khandelwal R, Dassanayake A, Conjeevaram H, Singh S
World J Diabetes. 2021; 12(9):1479-1493.
PMID: 34630901
PMC: 8472504.
DOI: 10.4239/wjd.v12.i9.1479.
Embedding assessment of liver fibrosis into routine diabetic review in primary care.
Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A
JHEP Rep. 2021; 3(4):100293.
PMID: 34179738
PMC: 8213901.
DOI: 10.1016/j.jhepr.2021.100293.
FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic.
Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M
Life (Basel). 2021; 11(2).
PMID: 33672864
PMC: 7917687.
DOI: 10.3390/life11020143.
Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan.
Sumida Y, Shima T, Mitsumoto Y, Katayama T, Umemura A, Yamaguchi K
Int J Mol Sci. 2020; 21(12).
PMID: 32570776
PMC: 7352222.
DOI: 10.3390/ijms21124337.
